Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review-Reference-Cited by-同舟云学术

Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review

Published:2024-04-02 Issue:4 Volume:20 Page:275-292
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Conti Valeria¹²,Bertini Nicola¹,Ricciardi Rosaria¹²,Stefanelli Berenice¹²,De Bellis Emanuela¹²,Sellitto Carmine¹²,Cascella Marco¹,Sabbatino Francesco¹,Corbi Graziamaria³,Pagliano Pasquale¹⁴,Filippelli Amelia¹²

Affiliation:

1. Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, SA, Italy

2. Clinical Pharmacology Unit, San Giovanni di Dio e Ruggi d’Aragona University Hospital, Salerno, Italy

3. Department of Translational Medical Sciences, University of Naples “Federico II”, Naples, Italy

4. Infectious Disease Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2024.2339397

Reference60 articles.

1. Treatment options for COVID-19: The reality and challenges

2. Experimental Pharmacotherapy for COVID-19: The Latest Advances

3. Lack of Benefit of Fluvoxamine for COVID-19

4. ESCMID COVID-19 living guidelines: drug treatment and clinical management

5. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment of COVID-19: lessons learned and future directions;Future Virology;2024-08-12

2. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis;Journal of Infection;2024-08

3. Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic;Expert Opinion on Drug Safety;2024-06-19